title: Combined treatment with haloperidol and trazodone in patients with tic disorders.
abstract: The combination of haloperidol and trazodone was evaluated in an open-label trial in 10 patients with chronic tic and Tourette's syndrome. We found a mean reduction of symptoms of 58.9% on the Yale Global Tic Severity Scale, with a statistically significant difference (p < 0.001) between the baseline and endpoint treatment conditions. This approach significantly reduces clinical symptoms, with the advantage of a lower dose of haloperidol than usual, with no side effects reported by the patients.
authors.affiliation: Child Neuropsychiatry, DSNV, G. Gaslini Institute, University of Genova, Italy. lfsdoc@tiscalinet.it
authors.forename: L
authors.initials: L
authors.lastname: Saccomani
authors.forename: P
authors.initials: P
authors.lastname: Rizzo
authors.forename: L
authors.initials: L
authors.lastname: Nobili
mesh_terms: D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D013981:Tic Disorders / Q000188:drug therapy* / Q000523:psychology; D014196:Trazodone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D006220:Haloperidol; D014196:Trazodone